Turn Therapeutics
GX-03
Eczema Atopic Dermatitis
Countdown
4days
Phase 2 readout · Jul 10, 2026
What's at stake
Phase 2 trial results for GX-03 in Eczema Atopic Dermatitis are due Jul 10, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT07355075: Phase 2 trial, sponsor Turn Therapeutics, drug GX-03. Primary completion date 2026-07-10 (estimated).”